Dr Triparna Sen speaks to ecancer about the biology and therapeutic options for STK11/KEAP1 co-mutant lung adenocarcinoma

She explains what KRAS mutations are and what is their frequency in solid-tumour oncology.

She highlights that this can be a targeted pathway for therapy. She then gives a high-level overview of KRAS tumour biology and its relation to lung cancer.

In the end, Dr Sen highlights the future implications of this study and how it can affect the future treatment of NSCLC.

For more information see here.